On November 3, 2025 TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, reported that its research on the potential role of the Delta Opioid Receptor in controlling the immunosuppressive capabilities of MDSCs was accepted for an oral presentation at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place in Orlando, FL from December 6-9, 2025. TuHURA will present these updated results along with a poster presentation of the effects of DOR inhibition on TAMs, another immunosuppressive cellular component critical to the tumorigenic microenvironment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present evidence demonstrating the expression of the DOR on MDSCs and TAMs, both of which are important immune suppressing cellular components of the body’s immune system that provide the ability to regulate inflammation and autoimmunity," stated Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "With our discovery of DOR expression, and that DOR activation is coupled to mechanisms by which both MDSCs and TAMs contribute to the immunosuppressive phenotype of the tumor microenvironment, we believe that the DOR represents a novel shared target for pharmacologic intervention to overcome resistance to cancer immunotherapies. TuHURA Biosciences is eager to leverage our discoveries around the DOR to develop highly potent and selective DOR inhibitors to create a new class of immune-modulating ADCs by linking a DOR inhibitor to our VISTA inhibiting antibody."

Oral Presentation Details:

Title: Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
Session: 201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis
Abstract Number: 14322
Presenter: Mike Turner, Ph.D. Vice President Immunology
Date and Time: December 7, 2025, from 5:15 – 5:30 PM ET
Location: W314 – OCC

Poster Presentation Details:

Title: Delta Opioid Receptor (DOR): A Novel Target for Reprogramming Tumor-Associated Macrophage (TAM) Immunosuppressive Phenotype to Overcome Acquired Resistance and Enhance the Effectiveness of Cancer Immunotherapies
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Abstract Number: 2568
Presenter: Krit Ritthipichai, D.V.M., Ph.D., Director of Immunology, TuHURA Biosciences
Date and Time: December 6, 2025, from 5:30 – 7:30 PM ET
Location: West Halls B3-B4 – OCCC

Additionally, The Moffitt Cancer Center, under its collaborative work with TuHURA, will present a poster outlining the pathogenic role of DOR expressing MDSCs in patients with myeloid dysplastic syndrome (MDS). Collectively, these three presentations at ASH (Free ASH Whitepaper) highlight the potential of DOR antagonism as a potential effective strategy warranting clinical investigation.

Title: Delta opioid receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes
Session: 636. Myelodysplastic Syndromes: Basic and Translational: Poster II
Abstract Number: 15332
Presenter: Erika Eksioglu, M.D., Department of Immunology, Moffitt Cancer Center
Date and Time: December 7, 2025, from 6:00 – 8:00 PM ET
Location: West Halls B3-B4 – OCCC

(Press release, TuHURA Biosciences, NOV 3, 2025, View Source [SID1234659304])